Several lung cancer, diffuse large B-cell melanoma, and lymphoma cases have reported CDK1 overexpression [33,56,57], while CDK2 overexpression has been observed in breast cancer, laryngeal squamous cell cancer, colorectal carcinomas, and melanomas [12,33]. This evidence concerns the gene CDK2 and breast carcinoma.